A Prospective, Study Evaluating the Efficacy of DOSE Formulations in Treatment of Melasma and Cutaneous Signs of Aging
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04137263|
Recruitment Status : Recruiting
First Posted : October 24, 2019
Last Update Posted : October 24, 2019
|Condition or disease||Intervention/treatment||Phase|
|Melasma||Other: DOSE formulation||Not Applicable|
Melasma is a hyperpigmentation disorder that presents as irregularly shaped macules on the face of women. The etiology is unknown however there is strong evidence that genetics, hormones, sun exposure can trigger and worsen the disease. Increased dermal vascularity and expression of angiogenic factors also seem to play a role. Melasma is a chronic and relapsing condition, that is difficult to treat, and can have a negative impact on quality of life.
Numerous treatments exist for melasma including topical lightening agents, chemical peels, and a variety of laser and light based options. Long-term management is difficult as topical agents can often cause irritation, burning, peeling and inflammatory hyperpigmentation. Light based therapies can also lead to relapse or worsening of the disease.
Melasma, in combination with photodamage from cumulative sun exposure and aging, can lead to a complex picture when making a skin care plan for a cosmetic patient. The custom D.O.S.E professional service can be utilized to make a personalized serum to improve skin discoloration and the visible signs of aging. The purpose of this study is to evaluate the efficacy of D.O.S.E formulations in the treatment of melasma and visible signs of aging.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Study Evaluating the Efficacy of DOSE Formulations in Treatment of Melasma and Cutaneous Signs of Aging|
|Actual Study Start Date :||October 1, 2019|
|Estimated Primary Completion Date :||October 1, 2020|
|Estimated Study Completion Date :||December 1, 2020|
Subjects will receive dose formulation for treatment of melasma
Other: DOSE formulation
- Improvement of Melasma [ Time Frame: Baseline to Day 120 ]change in Investigator MoPASI score
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04137263
|Contact: Daniel Leeperfirstname.lastname@example.org|
|Contact: Leslie Aguilaremail@example.com|
|United States, California|
|Cosmetic Laser Dermatology||Recruiting|
|San Diego, California, United States, 92121|
|Contact: Isabella C Guiha 858-657-1004 IGuiha@CLDerm.com|
|Principal Investigator:||Monica Boen, M.D.||Cosmetic Laser Dermatology|